SCHEMBL20435591

SCHEMBL20435591

Cc1cccc2cc(S(=O)(=O)c3ccccc3)c(=O)oc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.67
ERAP1 Q9NZ08 2/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
PABPC1 P11940 1/20 0.67
ADORA3 P0DMS8 3/20 0.57
ADORA1 P30542 2/20 0.57
ADORA2A P29274 1/20 0.57
RXFP1 Q9HBX9 3/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TP53 P04637 3/20 0.55
TDP1 Q9NUW8 1/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
PKM P14618 1/20 0.52
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
CA12 O43570 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830863 0.90 ADORA3 (0.56) ATMERAP1MEN1KMT2APABPC1
SCHEMBL20435592 0.84 MEN1 (0.62) ATMERAP1MEN1KMT2APABPC1
SCHEMBL20440775 0.84 ATM (0.69) ATMERAP1MEN1KMT2APABPC1
SCHEMBL21033122 0.79 RXFP1 (0.83) ATMERAP1MEN1KMT2APABPC1
SCHEMBL20435590 0.77 KDM4E (0.78) ATMERAP1MEN1KMT2APABPC1
SCHEMBL21032748 0.75 HTT (0.69) ATMERAP1MEN1KMT2APABPC1
SCHEMBL21033057 0.74 MAPT (0.82) ATMERAP1MEN1KMT2APABPC1
SCHEMBL20435593 0.74 NPSR1 (0.72) ATMERAP1MEN1KMT2APABPC1
SCHEMBL21032751 0.73 CA12 (0.65) ATMERAP1MEN1KMT2APABPC1
SCHEMBL21032905 0.72 ALDH1A1 (1.00) ATMERAP1MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 ATM 3419/4885ERAP1 3910/4885MEN1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.